Leucine-rich α2-glycoprotein as a potential biomarker for immune-related colitis after anti-PD-1 therapy: A report of case series

Leucine-rich α2-glycoprotein as a potential biomarker for immune-related colitis after anti-PD-1 therapy: A report of case series: The use of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis is one of the main therapies for advanced non-small-cell lung cancer (NSCLC). With the increasing use of ICIs, immune-related adverse events (irAEs) are also been increasing reported.1 Immune-related colitis is an important irAE.2 Grade 3 immune-related colitis develops in 1%–2% of the patients after therapy with ICIs and can lead to further deterioration, occasionally resulting in fatal outcomes.1 Similar to inflammatory bowel diseases (IBDs) cases, some immune-related colitis patients show resistance to steroid therapy and, therefore, need further medications, including infliximab.